Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79920.580.1002%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Outlook Therapeutics Inc (OTLK) Stock Price, Quote, News & History

OTLKNASDAQ
Trade with Public
Trade with Public
$0.6665
0.01752.7%
At close: Sep 4, 5:00 PM EST
$0.6700
0.00350.53%
After Hours: Sep 4, 7:52 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Outlook Therapeutics (OTLK) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$0.66
Close
$0.67
Volume / Avg.
6.40M / 17.47M
Day Range
$0.65 - $0.70
52 Wk Range
0.16 - 2.54
Market Cap
$162.59M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
38
Short Interest
8.69%
Days to Cover
1

Recent Outlook Therapeutics Inc News

5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In

U.S. stocks fell, but S&P 500 gained 0.4% for 3rd week. Wall Street analysts make new stock picks daily, Benzinga's data can help make better trades.
Avi Kapoor

S&P 500 Hits New Record High Following PPI Data: Investor Sentiment Improves, Fear Index Remains In ‘Greed’ Zone

CNN Fear & Greed index showed improved market sentiment, with S&P 500 hitting a new record high after PPI data release. Nasdaq up 0.81%.
Avi Kapoor

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Outlook Therapeutics (NASDAQ: OTLK) to release Q3 earnings on Aug. 14. Analysts expect a loss of 8 cents/share. Analysts rate it Neutral or Buy.
Avi Kapoor

Outlook Therapeutics Targets Multibillion Dollar Ophthalmology Market With New Drug After FDA Rejection

The FDA approved LYTENAVA by Outlook Therapeutics, marking the first ophthalmic bevacizumab for wet AMD in the lucrative US retina market.
Vandana Singh

This General Motors Analyst Turns Bulish; Here Are Top 5 Upgrades For Monday

Wall Street analysts upgrade GM, RIVN, OTLK, F, and MBLY. See their ratings on Benzinga's analyst ratings page before buying.
Avi Kapoor

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-56.15M
Investing Cash Flow (TTM)
-
Financing Cash Flow (TTM)
60.60M
Free Cash Flow (TTM)
-56.15M
Capital Expenditure (TTM)
-
Net Change in Cash (TTM)
2.34M

Analyst Trends and Forecast

1
Mar
1
May
1
Jun
1
1
Jul
1
Aug
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
3.8
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$168.93M
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
-
PB Ratio (TTM)
-
Earnings Yield % (TTM)
-107.73%
Earnings Yield % (FWD)
-9.23%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
-$0.04

Company Debt

Total Debt
$18.23M
LT Debt
-
LT Debt Issuance (TTM)
$0
LT Debt Repayment (TTM)
-$2.33M
Total Cash
$11.24M
Debt to Equity
-
Issuance of Debt (TTM)
-$2.33M
Repayment of Debt (TTM)
-$2.33M

Key Statistics

Open
$0.66
Close
$0.67
Volume / Avg.
6.40M / 17.47M
Day Range
$0.65 - $0.70
52 Wk Range
0.16 - 2.54
Market Cap
$162.59M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
38
Short Interest
8.69%
Days to Cover
1

About

Sector
Health Care
Industry
Biotechnology
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an oph...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Outlook Therapeutics (OTLK) stock?

A

You can purchase shares of Outlook Therapeutics (NASDAQ:OTLK) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Outlook Therapeutics (OTLK) competitors?

Q

What is the forecast, or price target, for Outlook Therapeutics (OTLK) stock?

A

Outlook Therapeutics has a consensus price target of $3.86.

Q

What is the current price for Outlook Therapeutics (OTLK)?

A

The stock price for Outlook Therapeutics (NASDAQ: OTLK) is $0.67 last updated September 4, 2026 at 7:52 PM EDT.

Q

Does Outlook Therapeutics (OTLK) pay a dividend?

A

There are no upcoming dividends for Outlook Therapeutics.

Q

When is Outlook Therapeutics (NASDAQ:OTLK) reporting earnings?

A

Outlook Therapeutics does not have any upcoming earnings scheduled.

Q

Is Outlook Therapeutics (OTLK) going to split?

A

There is no upcoming split for Outlook Therapeutics.

Q

What sector and industry does Outlook Therapeutics (OTLK) operate in?

A

Outlook Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved